Summary
Collegium Pharmaceutical, Inc. (Collegium) is a specialty pharmaceutical company, which develops products for the treatment of chronic pain that incorporate its DETERx oral drug delivery technology. Collegium’s lead candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone that uses DETERx technology for the long-term continuous management of pain. The company obtained Fast Track designation from FDA for Xtampza ER in pain management. Its other pipeline products include COL-172 oxymorphone, for the relief of moderate to severe pain; COL-195 hydrocodone and COL-196 morphine, for the relief of pain; and COL-171 methylphenidate, for the treatment of attention deficit hyperactivity disorder. The company collaborates with organizations for product licensing, and technology development opportunities. Collegium is headquartered in Canton, Massachusetts, the US.
Collegium Pharmaceutical, Inc. Key Recent Developments
Mar 15, 2016: Collegium Reports 2015 Financial Results and Provides Corporate Update
Dec 28, 2015: Collegium Pharmaceutical Provides Update on Orange Book-Listed Patent Suits
Dec 14, 2015: Collegium Added to the NASDAQ Biotechnology Index
Nov 12, 2015: Collegium Reports Third Quarter Financial Results and Provides Corporate Update
Aug 12, 2015: Collegium Reports Second Quarter Financial Results and Provides Corporate Update
This comprehensive SWOT profile of Collegium Pharmaceutical, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Collegium Pharmaceutical, Inc. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).
The profile contains critical company information including*,
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Collegium Pharmaceutical, Inc. (Collegium) is a specialty pharmaceutical company, which develops products for the treatment of chronic pain that incorporate its DETERx oral drug delivery technology. Collegium’s lead candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone that uses DETERx technology for the long-term continuous management of pain. The company obtained Fast Track designation from FDA for Xtampza ER in pain management. Its other pipeline products include COL-172 oxymorphone, for the relief of moderate to severe pain; COL-195 hydrocodone and COL-196 morphine, for the relief of pain; and COL-171 methylphenidate, for the treatment of attention deficit hyperactivity disorder. The company collaborates with organizations for product licensing, and technology development opportunities. Collegium is headquartered in Canton, Massachusetts, the US.
Collegium Pharmaceutical, Inc. Key Recent Developments
Mar 15, 2016: Collegium Reports 2015 Financial Results and Provides Corporate Update
Dec 28, 2015: Collegium Pharmaceutical Provides Update on Orange Book-Listed Patent Suits
Dec 14, 2015: Collegium Added to the NASDAQ Biotechnology Index
Nov 12, 2015: Collegium Reports Third Quarter Financial Results and Provides Corporate Update
Aug 12, 2015: Collegium Reports Second Quarter Financial Results and Provides Corporate Update
This comprehensive SWOT profile of Collegium Pharmaceutical, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Collegium Pharmaceutical, Inc. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).
The profile contains critical company information including*,
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Frequently Asked Questions
This market study covers the global and regional market with an
in-depth analysis of the
overall growth prospects...
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by
highlighting information on
different aspects including drivers, restraints...
Pre-order Enquiry
Download Free Sample








